Clinical Impact of New Data From Boston 2016
Source: Clinical Impact of New Hepatology Data From Boston 2016*

Slideset

Clinical Impact of New Data From Boston 2016

In this downloadable slideset, expert faculty members Ira M. Jacobson, MD, and Stefan Zeuzem, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File size: 542 KB
Date posted: 11/30/2016
  • How I Manage Patients With HCV After DAA Treatment Failure

    Jordan J. Feld MD, MPH - 1/19/2016    6 comments / Last Comment: 6/25/2016
    In the few HCV patients for whom DAA treatment fails, I consider a combination of 2 or more of the following: switching to a different DAA class, treating for longer, or adding ribavirin.
  • Weighing the Treatment Options for Genotype 3 HCV Infection in Cirrhotics

    Mark S. Sulkowski MD - 2/25/2016    3 comments / Last Comment: 4/11/2016
    In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.
  • Hepatitis B Reactivation: Sometimes Scratching the Surface May Be Better Than Getting to the Core

    Jordan J. Feld MD, MPH - 1/24/2017    2 comments / Last Comment: 2/21/2017
    Does the need for HBV reactivation screening vary by the potency of immunosuppressive therapy? Here’s my take.
  • How Recent Guideline Updates on HBV Screening in HCV-Infected DAA Recipients Affect Clinical Practice

    Norah Terrault MD, MPH - 11/23/2016    1 comment / Last Comment: 11/29/2016
    How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.
  • How Data From the 2016 Boston Hepatology Meeting Will Influence Future HCV Patient Management

    Mark S. Sulkowski MD - 1/31/2017    1 comment / Last Comment: 2/13/2017
    The 2016 hepatology meeting in Boston offered future solutions to some of my most vexing patient challenges.